Cancer Immunotherapy Market Revenue 2024 to 2034
Cancer Immunotherapy Market Revenue 2024 to 2034
The cancer immunotherapy market will rise from USD 122.99 Bn in 2024 to USD 338.36 Bn by 2034, at a 10.65% CAGR, driven by CAR-T therapies, checkpoint inhibitors, and the growing shift toward precision oncology.
Report ID: 10648
|
Format: Databook
|
Published: August 2025
|
Delivery: Immediate
Download Sample
Customisation Request
Revenue,
USD 122.99 Bn
Forecast Year,
USD 338.36 Bn
CAGR, 2025 -
10.65%
Report Coverage
Worldwide
Reviewed By
Aditi Shivarkar
Reviewed By
Aman Singh
Cancer Immunotherapy Market Size Analysis
Cancer Immunotherapy Market Size By Therapy 2024 to 2034 (USD )
| Therapy | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Monoclonal Antibodies | 54.12 | 60.05 | 66.63 | 73.94 | 82.05 | 91.05 | 101.04 | 112.12 | 124.42 | 138.08 | 153.24 |
| Checkpoint Inhibitors | 24.60 | 27.35 | 30.41 | 33.81 | 37.59 | 41.80 | 46.48 | 51.68 | 57.47 | 63.90 | 71.06 |
| Cell Therapies | 17.22 | 19.12 | 21.23 | 23.58 | 26.18 | 29.08 | 32.29 | 35.86 | 39.82 | 44.23 | 49.12 |
| Cancer Vaccines | 12.30 | 13.45 | 14.70 | 16.06 | 17.54 | 19.16 | 20.92 | 22.84 | 24.92 | 27.19 | 29.65 |
| Cytokines/Others | 14.76 | 16.12 | 17.61 | 19.23 | 20.99 | 22.91 | 25.00 | 27.26 | 29.73 | 32.40 | 35.30 |
Cancer Immunotherapy Market Size By Indication 2024 to 2034 (USD )
| Indication | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Lung | 29.52 | 32.56 | 35.92 | 39.63 | 43.72 | 48.23 | 53.20 | 58.69 | 64.75 | 71.43 | 78.80 |
| Breast | 19.68 | 21.83 | 24.23 | 26.88 | 29.82 | 33.09 | 36.71 | 40.73 | 45.18 | 50.13 | 55.61 |
| Melanoma | 12.30 | 13.71 | 15.29 | 17.05 | 19.00 | 21.18 | 23.61 | 26.31 | 29.32 | 32.67 | 36.41 |
| Hematologic | 24.60 | 26.93 | 29.49 | 32.29 | 35.34 | 38.69 | 42.35 | 46.34 | 50.72 | 55.50 | 60.72 |
| Others | 36.90 | 41.04 | 45.65 | 50.78 | 56.48 | 62.82 | 69.86 | 77.69 | 86.39 | 96.07 | 106.83 |
Cancer Immunotherapy Market Size By End-use 2024 to 2034 (USD )
| End-use | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals | 71.33 | 78.85 | 87.17 | 96.35 | 106.51 | 117.74 | 130.15 | 143.87 | 159.03 | 175.80 | 194.33 |
| Clinics | 34.44 | 38.24 | 42.46 | 47.15 | 52.35 | 58.12 | 64.53 | 71.65 | 79.55 | 88.32 | 98.05 |
| Others | 17.22 | 19.00 | 20.96 | 23.12 | 25.51 | 28.14 | 31.04 | 34.25 | 37.78 | 41.68 | 45.98 |
Cancer Immunotherapy Market Size By Region 2024 to 2034 (USD )
| Region | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| North America | 41.82 | 46.08 | 50.78 | 55.96 | 61.66 | 67.94 | 74.86 | 82.48 | 90.87 | 100.11 | 110.28 |
| Europe | 34.44 | 38.08 | 42.10 | 46.56 | 51.48 | 56.92 | 62.94 | 69.59 | 76.95 | 85.08 | 94.07 |
| Asia Pacific | 36.90 | 40.84 | 45.19 | 50.02 | 55.36 | 61.27 | 67.81 | 75.05 | 83.06 | 91.93 | 101.74 |
| Latin America | 4.92 | 5.43 | 6.00 | 6.63 | 7.33 | 8.09 | 8.94 | 9.87 | 10.91 | 12.05 | 13.31 |
| Middle East & Africa | 4.92 | 5.66 | 6.50 | 7.45 | 8.54 | 9.78 | 11.18 | 12.78 | 14.59 | 16.64 | 18.96 |
Proceed To Buy
Proceed To CheckoutMake Every Move Strategic. Get Insights, Fully Customized
- On-Demand Metrics & KPIs
- Industry-Specific Dashboards
- Quick Turnaround, No Compromises
Quick Contact
- NA : +1 804 441 9344
- APAC : +91 9356 9282 04
- EU : +44 7782 560 738
- sales@precedenceresearch.com
